350 related articles for article (PubMed ID: 21948318)
1. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
Wu Y; Levons J; Narang AS; Raghavan K; Rao VM
AAPS PharmSciTech; 2011 Dec; 12(4):1248-63. PubMed ID: 21948318
[TBL] [Abstract][Full Text] [Related]
2. A new approach to accelerated drug-excipient compatibility testing.
Sims JL; Carreira JA; Carrier DJ; Crabtree SR; Easton L; Hancock SA; Simcox CE
Pharm Dev Technol; 2003; 8(2):119-26. PubMed ID: 12760562
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hydroperoxides in common pharmaceutical excipients.
Wasylaschuk WR; Harmon PA; Wagner G; Harman AB; Templeton AC; Xu H; Reed RA
J Pharm Sci; 2007 Jan; 96(1):106-16. PubMed ID: 16917844
[TBL] [Abstract][Full Text] [Related]
4. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
[TBL] [Abstract][Full Text] [Related]
5. Impact Of Excipient Variability On Drug Product Processing And Performance.
Peng Soh JL; Liew CV; Sia Heng PW
Curr Pharm Des; 2015; 21(40):5890-9. PubMed ID: 26446469
[TBL] [Abstract][Full Text] [Related]
6. Purification of pharmaceutical excipients with supercritical fluid extraction.
Ashraf-Khorassani M; Taylor LT; Waterman KC; Narayan P; Brannegan DR; Reid GL
Pharm Dev Technol; 2005; 10(4):507-16. PubMed ID: 16370180
[TBL] [Abstract][Full Text] [Related]
7. Excipient variability and its impact on dosage form functionality.
Dave VS; Saoji SD; Raut NA; Haware RV
J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
[TBL] [Abstract][Full Text] [Related]
8. Identification of pharmaceutical impurities in formulated dosage forms.
Pan C; Liu F; Motto M
J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
[TBL] [Abstract][Full Text] [Related]
9. An investigation into the effects of excipient particle size, blending techniques and processing parameters on the homogeneity and content uniformity of a blend containing low-dose model drug.
Alyami H; Dahmash E; Bowen J; Mohammed AR
PLoS One; 2017; 12(6):e0178772. PubMed ID: 28609454
[TBL] [Abstract][Full Text] [Related]
10. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
Chadha R; Bhandari S
J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
[TBL] [Abstract][Full Text] [Related]
11. Impact of excipient interactions on solid dosage form stability.
Narang AS; Desai D; Badawy S
Pharm Res; 2012 Oct; 29(10):2660-83. PubMed ID: 22707362
[TBL] [Abstract][Full Text] [Related]
12. Practical considerations in development of solid dosage forms that contain cyclodextrin.
Miller LA; Carrier RL; Ahmed I
J Pharm Sci; 2007 Jul; 96(7):1691-707. PubMed ID: 17243148
[TBL] [Abstract][Full Text] [Related]
13. Elemental Impurities in Pharmaceutical Excipients.
Li G; Schoneker D; Ulman KL; Sturm JJ; Thackery LM; Kauffman JF
J Pharm Sci; 2015 Dec; 104(12):4197-4206. PubMed ID: 26398581
[TBL] [Abstract][Full Text] [Related]
14. Excipient-related impurities in liposome drug products.
Wang C; Gamage PL; Jiang W; Mudalige T
Int J Pharm; 2024 May; 657():124164. PubMed ID: 38688429
[TBL] [Abstract][Full Text] [Related]
15. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
[TBL] [Abstract][Full Text] [Related]
16. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
[TBL] [Abstract][Full Text] [Related]
17. Utilizing quantitative certificate of analysis data to assess the amount of excipient lot-to-lot variability sampled during drug product development.
Kushner J
Pharm Dev Technol; 2013; 18(2):333-42. PubMed ID: 21877870
[TBL] [Abstract][Full Text] [Related]
18. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
Jorgensen L; Hostrup S; Moeller EH; Grohganz H
Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
[TBL] [Abstract][Full Text] [Related]
19. ICH Q3D Drug Product Elemental Risk Assessment: The Use of An Elemental Impurities Excipients Database.
Torres S; Boetzel R; Gatimu E; Gomes DZ; King F; Kocks G; Jones R; Day C; Lewen N; Harris L; Teasdale A
J Pharm Sci; 2022 May; 111(5):1421-1428. PubMed ID: 34673095
[TBL] [Abstract][Full Text] [Related]
20. Excipient Stability in Oral Solid Dosage Forms: A Review.
Darji MA; Lalge RM; Marathe SP; Mulay TD; Fatima T; Alshammari A; Lee HK; Repka MA; Narasimha Murthy S
AAPS PharmSciTech; 2018 Jan; 19(1):12-26. PubMed ID: 28895106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
